HIV/AIDS HAART
GNB3 C825T polymorphism associated with short-term success of HAART treatment
Published in AIDS Weekly, February 6th, 2006
"Analyses were based on a cohort of 55 HIV infected patients whose treatment was changed due to therapy failure. Vital load, CD4+ and CD8+ cell Counts were determined before therapy and after 8 weeks and 16-32 weeks, respectively," scientists in Germany report.
According to N.H. Brockmeyer and colleagues at Ruhr University of Bochum, "GNB3 genotyping was performed using pyrosequencing. Chemotaxis of purified CD4+ cello was quantified in a Boyden chamber using stromal cell-derived factor 1 alpha (SDF-1 alpha) as a stimulus.
"Age gender, route of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-02-06)
More Articles from AIDS Weekly
- HIV/AIDS Drug Development
Bifunctional HIV-1 inhibitors simultaneously block CD4 and CCR5 receptors - HIV/AIDS Drug Interaction
Ritonavir increases systemic exposure of prednisolone - HIV/AIDS Drug Resistance
Recent HIV-1 seroconverters more likely to have transmitted drug resistance - HIV/AIDS Epidemiology
Frequency of HIV/AIDS protective SDF1-3'A gene high among blood donors in Crete - HIV/AIDS HAART
HIV RNA sustained below 20 copies/mL may prevent 184V mutation in CD4 cell DNA - Allergy & Immunology
Cytomegalovirus infection inhibits immune responses generated against P. carinii - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
